Skip to main content

Table 3 Sex differences in SIRs of malignancy in patients with SLE compared to general populations

From: Increased risk of malignancy in patients with systemic lupus erythematosus: population-based cohort study in Korea

Type of malignancy Total
(n=17,854)
Female
(n=16,143)
Male
(n=1711)
Overall malignancies 1.75 (1.63, 1.87) 1.72 (1.60, 1.84) 2.05 (1.65, 2.46)
Solid malignancy 1.65 (1.53, 1.77) 1.64 (1.51, 1.76) 1.78 (1.39, 2.16)
 Breast and reproductive system 1.45 (1.23, 1.66) 1.43 (1.21, 1.65) 1.76 (0.72, 2.81)
 Thyroid 1.58 (1.33, 1.82) 1.55 (1.30, 1.80) 2.56 (0.51, 4.61)
 Liver 1.86 (1.40, 2.32) 1.98 (1.46, 2.50) 1.32 (0.40, 2.23)
 Colon 1.73 (1.30, 2.16) 1.69 (1.23, 2.16) 1.91 (0.73, 3.10)
 Lung 1.80 (1.20, 2.41) 1.73 (1.05, 2.41) 2.03 (0.70, 3.35)
 Pancreas 1.96 (1.28, 2.63) 2.00 (1.27, 2.72) 1.64 (0, 3.50)
 Stomach 1.09 (0.71, 1.48) 1.17 (0.73, 1.60) 0.76 (0.02, 1.51)
 Bladder 2.44 (1.06, 3.83) 2.74 (1.04, 4.44) 1.58 (0, 3.77)
 Head and neck 2.65 (1.08, 4.21) 2.71 (0.94, 4.47) 2.41 (0, 5.75)
 Kidney 1.78 (0.68, 2.89) 1.06 (0.13, 1.99) 5.54 (0.68, 10.39)
 Biliary tract 1.03 (0.27, 1.80) 0.69 (0.01, 1.37) 3.00 (0, 6.39)
 Brain and central nervous system 0.91 (0.11, 1.72) 1.01 (0.12, 1.89) NC
 Larynx 2.59 (1.00, 6.17) 5.02 (0, 11.98) NC
Haematology malignancy 5.87 (4.48, 7.27) 5.22 (3.80, 6.64) 9.89 (5.05, 14.74)
 Non-Hodgkin lymphoma 6.24 (4.20, 8.27) 5.33 (3.32, 7.34) 12.71 (4.41, 21.02)
 Multiple myeloma 8.19 (3.90, 12.48) 8.95 (4.08, 13.82) 3.90 (0, 11.53)
 Leukaemia 3.64 (1.58, 5.70) 2.87 (0.88, 4.86) 7.80 (0.16, 15.45)
 Hodgkin lymphoma 7.53 (1.00, 16.05) 9.41 (0, 20.06) NC
  1. The standardised incidence ratio (SIR) was presented with 95% confidence interval. CI, confidence interval; NC, not calculated